These results were correlated with a decrease in the cancer stem cell (ALDHhighCD44high) fraction mediated by Tocilizumab in vitro, and with the observation the cancer stem cells express higher levels of IL-6R when compared to control cells. This evidence concerns the gene IL6R and cancer.